Pro- and Anti-inflammatory Forms of Interleukin-1 in the Tear Fluid and Conjunctiva of Patients with Dry-Eye Disease

Abraham Solomon,[1] Dilek Dursun,[1] Zuguo Liu,[1,2] Yuhuan Xie,[1,2] Angelo Macri,[1] and Stephen C. Pflugfelder[1]

PURPOSE. To compare the expression of the pro- and anti-inflammatory forms of interleukin (IL)-1 in the tear fluid and conjunctival epithelium of normal eyes and those with dry-eye disease.

METHODS. The concentrations of IL-1α, IL-1β (precursor and mature forms), and IL-1 receptor antagonist (IL-1Ra) were measured by ELISA in tear fluid samples obtained from normal individuals and patients with dry eye who had rosacea-associated meibomian gland disease (MGD) or Sjögren's syndrome (SS) aqueous tear deficiency (ATD). These cytokines were also measured in normal tear fluid before and after nasal stimulation to induce reflex tearing. The relative expression of these cytokines was evaluated in conjunctival impression cytology specimens and conjunctival biopsy tissue obtained from normal subjects and SS ATD–affected patients using immunofluorescent staining. Matrix metalloproteinase (MMP)-9 concentration and activity in the tear fluid were evaluated with gelatin zymography and with an MMP-9 activity assay kit, respectively.

RESULTS. Compared with normal subjects, the concentration of IL-1α and mature IL-1β in the tear fluid was increased, and the concentration of precursor IL-1β was decreased in patients with MGD ($P < 0.05$, $P = 0.02$, and $P < 0.01$, respectively) and SS ATD ($P < 0.001$, $P = 0.02$, and $P < 0.001$, respectively). There was no significant change in the concentration of IL-1α, precursor IL-1β, and IL-1Ra in reflex tear fluid, indicating that the lacrimal glands may secrete these cytokines. The activity of MMP-9, a physiological activator of IL-1β, was significantly elevated in the tear fluid of both dry-eye groups compared with normal subjects. A strong positive correlation was observed between the intensity of corneal fluorescein staining and the tear fluid IL-1α concentration ($r^2 = 0.17$, $P < 0.02$) and the mature-to-precursor IL-1β ratio ($r^2 = 0.46$, $P < 0.001$). Positive immunofluorescent staining for IL-1α, mature IL-1β, and IL-1Ra was observed in a significantly greater percentage of conjunctival cytology specimens from eyes with SS ATD than in those from normal eyes ($P < 0.01$ for IL-1α, $P < 0.009$ for mature IL-1β, and $P < 0.05$ for IL-1Ra).

CONCLUSIONS. Dry-eye disease is accompanied by an increase in the proinflammatory forms of IL-1 (IL-1α and mature IL-1β) and a decrease in the biologically inactive precursor IL-1β in tear fluid. Increased protease activity on the ocular surface may be one mechanism by which precursor IL-1β is cleaved to the mature, biologically active form. The conjunctival epithelium appears to be one source of the increased concentration of IL-1 in the tear fluid of patients with dry-eye disease. These results suggest that IL-1 may play a key role in the pathogenesis of keratoconjunctivitis sicca. (*Invest Ophthalmol Vis Sci.* 2001; 42:2283–2292)

There is increasing evidence that dry eye is accompanied by subclinical ocular surface inflammation. The evidence for this inflammation includes increased expression of immune activation markers, such as HLA-DR, intercellular adhesion molecule (ICAM)-1, and CD-40, by the conjunctival epithelium and infiltration of the conjunctiva by inflammatory cells.[1-7] The importance of inflammation in the pathogenesis of dry eye is underscored by reports that the signs and symptoms of dry eye markedly improve with anti-inflammatory therapies such as glucocorticosteroids and cyclosporin.[8,9]

Our group has previously evaluated the levels of the inflammatory cytokines that are capable of modulating the expression of these inflammatory markers and of stimulating leukocyte chemotaxis onto the ocular surface of dry eyes. Our studies showed that the levels of RNAs encoding a number of different inflammatory cytokines, including interleukin (IL)-1, -6, and -8 and TNF-α, were elevated in the conjunctival epithelium of patients with Sjögren's syndrome (SS) keratoconjunctivitis sicca (KCS) compared with normal subjects.[10] The levels of IL-1 and -8 RNA are directly correlated with the intensity of corneal fluorescein staining and are inversely correlated with conjunctival goblet cell density. In a subsequent study, we found that the concentration of matrix metalloproteinase (MMP)-9, the principal MMP enzyme produced by the corneal epithelium and a key factor in the pathogenesis of sterile corneal ulceration, increases as tear clearance decreases.[11] The mechanism by which these inflammatory and matrix-degrading factors are upregulated in dry-eye disease has not been established.

The proinflammatory cytokine IL-1 is an important mediator of inflammation and immunity.[12] IL-1 has been implicated in the pathogenesis of human inflammatory diseases, such as septic shock, rheumatoid arthritis, and periodontitis,[13-15] as well as the corneal and ocular surface diseases rosacea, bullous keratopathy, keratoconus, and sterile corneal ulceration.[11,16-17] Both proinflammatory forms of IL-1 (IL-1α and -1β) are multifunctional cytokines that in general produce similar biological effects, although these may vary among different cell types and organ systems.[19,20] IL-1 is a potent inducer of other inflammatory cytokines such as IL-6 and -8, TNF-α, and granulocyte-macrophage colony-stimulating factor (GM-CSF).[21,22] It also stimulates production of MMP enzymes by epithelial and inflammatory cells.[23] Both IL-1α and -1β are

TABLE 1. Demographic Characteristics of Study Patients

Group	n	Gender	Age	Age Range
Normal 1	10	6 women, 4 men	32 ± 6.6*	24–44
Normal 2	7	4 women, 3 men	46 ± 8.6†	35–57
SS ATD	9	8 women, 3 men	68 ± 9.1	53–80
MGD	13	7 women, 6 men	55 ± 16.3	25–73

Age is expressed as mean years ± SD.
* Normal 1 vs SS ATD $P < 0.001$; Normal 1 vs MGD $P = 0.0004$.
† Normal 2 vs SS ATD $P = 0.001$; Normal 2 vs MGD $P = 0.36$.

synthesized as precursor proteins with a molecular mass of approximately 33 kDa.[19] The precursor and the mature 17-kDa forms of IL-1α are both biologically active.[19] In contrast, the precursor form of IL-1β possesses minimal biological activity and requires cleavage to the 17-kDa mature form to become active.[19] This conversion occurs within cells by IL-1β–converting enzyme (also known as ICE or caspase 1) and in the extracellular environment by a number of proteases, including leukocyte elastase, granzyme A, and MMP-2 and -9.[12,24,25] Among a number of different MMPs evaluated, MMP-9 was found to be the most efficient activator of precursor IL-1β.[25]

IL-1Ra is a cytokine that inhibits the activities of the proinflammatory forms of IL-1 by competitively binding to the type 1 IL-1 receptor.[26] Administration of IL-1Ra has been found to be clinically beneficial in the treatment of arthritis and prevention of corneal transplant rejection in experimental models.[14,27] Both proinflammatory forms (IL-1α and -1β) and the anti-inflammatory form (IL-1Ra) of IL-1 have been detected in the human corneal epithelium.[28–31] IL-1Ra has also been detected in human conjunctival epithelial cells.[32] IL-1α and -1β have also been detected in human tear fluid.[11,33]

We hypothesized that increased concentration and/or activity of IL-1 could be an initiating factor for the observed ocular surface immunopathology of dry eye. This study was designed to test this hypothesis by comparing the concentrations of IL-1α, inactive precursor and active mature IL-1β and IL-1Ra in tear fluid samples obtained from patients with dry-eye disease who had rosacea-associated meibomian gland disease (MGD) or Sjögren's syndrome (SS) aqueous tear deficiency (ATD) and normal asymptomatic subjects. The relative levels of expression of the IL-1 family of cytokines in the conjunctival epithelium of normal subjects and patients with SS ATD, the dry-eye condition that has been reported to involve the most severe

KCS,[34] were compared using immunofluorescent staining. The activity of MMP-9, a protease that activates precursor IL-1β in the extracellular environment was also evaluated. Finally, the tear fluid concentrations of lactoferrin, a protein secreted by the lacrimal glands into human tears that inhibits the formation of reactive oxygen species that can damage cells and promote production and release of IL-1 was measured.[35,36]

MATERIALS AND METHODS

Materials

Rabbit anti-human polyclonal antibodies specific for IL-1α, the precursor and mature forms of IL-1β, and recombinant precursor and mature human IL-1β and ELISA kits for the precursor and mature forms of IL-1β were purchased from Cistron (Pine Brook, NJ); ELISA kits for IL-1α and IL-1Ra and recombinant human IL-1α and IL1-Ra and polyclonal antisera for IL-1Ra from R&D Systems (Minneapolis, MN); FITC-conjugated secondary antibodies from Caltag Laboratories (Burlingame, CA); and Texas red-conjugated secondary antibodies from Molecular Probes (Eugene, OR).

Patient Selection

This study was conducted according to a protocol approved by the University of Miami School of Medicine Institutional Review Board and in accordance with the tenets of the Declaration of Helsinki. Informed consent was obtained from participants after the nature and possible consequences of the study were explained.

Tear fluid samples were obtained from 9 patients with primary SS ATD, 1 patient with non-SS ATD, 13 patients with rosacea-associated MGD, and 17 normal subjects. The demographic characteristics of these patients are presented in Table 1. One group of normal subjects consisted of six women and four men who had no history of eye disease or ocular surgery, did not use eye drops, and had no ocular irritation symptoms. All the subjects had a Schirmer 1 test score greater than 15 mm, normal meibomian glands, and no corneal fluorescein staining. This group was used for evaluating tear proteins in unstimulated tear fluid. A second group of asymptomatic normal subjects (four women and three men) who met the same criteria was used for evaluating the effects of reflex tearing on the concentration of the IL-1 family of cytokines in tear fluid. All normal subjects were recruited from the employees of the Bascom Palmer Eye Institute.

The SS group consisted of eight women and one man. Diagnosis of primary SS was based on criteria proposed by Fox et al.[37] and included the following: (1) a Schirmer 1 test score of 5 mm or less in at least one eye, (2) interpalpebral zone fluorescein dye staining of the conjunctiva

TABLE 2. Concentrations of IL-1 Family Cytokines in Unstimulated Tear Fluid Obtained from Normal Subjects and Patients with MGD and SS ATD

Cytokine	Normal ($n = 10$)	MGD ($n = 13$)	SS ($n = 9$)	P
IL-1α	43.1 ± 24	253.7 ± 90	443.3 ± 128.5	*<0.05 †<0.001
Precursor IL-1β	379.2 ± 73	54.6 ± 16	21.2 ± 10	*<0.01 †<0.0001
Mature IL-1β	29.8 ± 10	187.7 ± 72	80.9 ± 22	*0.02 †0.02
Precursor-mature IL-1β	19.1 ± 5	1.17 ± 0.7	0.35 ± 0.2	*†0.0001
IL-1 Ra ($\times 10^5$)	2.95 ± 1.27	9.40 ± 2.54	23.96 ± 12.35	*†NS
IL-1 Ra/IL-1α ($\times 10^3$)	27.86 ± 20.57	6.95 ± 6.6	5.01 ± 6.28	*0.012 †0.007
IL-1 Ra/mature IL-1β ($\times 10^3$)	40.5 ± 18.39	14.28 ± 42.59	70.29 ± 44.15	*0.0016 †NS

Data are expressed as mean picograms per milliliter.
* Normal vs MGD.
† Normal vs SS.

A

B

FIGURE 1. **(A)** Correlation between IL-1α concentration in tears and corneal fluorescein staining scores. **(B)** Correlation between mature-precursor IL-1β ratio in tears and corneal fluorescein staining scores.

and cornea, (3) xerostomia, (4) elevated serum autoantibody titers (antinuclear antibody and/or rheumatoid factor titer ≥1:160), and (5) symptoms of moderate to severe ocular irritation.[37] The patient with non-SS ATD was a 67-year-old woman who had a Schirmer 1 test score of 4 mm in both eyes and interpalpebral corneal and conjunctival staining, but did not have xerostomia or serum autoantibodies.

The MGD group consisted of seven women and six men with the chief symptoms of ocular irritation and/or redness that was diagnosed as ocular rosacea with MGD, according to previously reported criteria.[38] Corneal fluorescein staining was graded using a previously reported method.[39] The cornea was examined under blue-light illumination 2 minutes after instillation of 5 μl 2% fluorescein into the tear film. The intensity of the corneal fluorescein staining was graded in each of four quadrants on the cornea (temporal, nasal, superior, inferior) using a standardized four-point scale (0, no staining; 1, mild; 2, moderate; and 3, intense). The range of staining scores was 0 to 12. Patients with dry eye were excluded if they had any clinical signs of external ocular infection, including staphylococcal blepharitis or bacterial conjunctivitis.

Tear Fluid Collection and Sample Extraction

For experiments comparing the concentrations of proteins in unstimulated tear fluid, a tear fluid sample was collected from the inferior tear meniscus of both eyes, causing the least irritation possible, using a preweighed polyester wick (Transorb rods; American Filtrona, Richmond, VA) to obtain the sample, as previously described.[11,40] The volume of collected tears was determined by reweighing the rods

TABLE 3. Poststimulation Tear Fluid Concentrations of IL-1α, Precursor IL-1β, and IL-1Ra in Seven Normal Subjects

Cytokine	Prestimulation	Poststimulation 1 (1 minute)	Poststimulation 2 (5 minutes)	P*
IL-1α	53.6 ± 26.8†	35.2 ± 10.0	108.7 ± 48.6	NS
Precursor IL-1β	712 ± 395‡	92.1 ± 68	384.7 ± 188	NS
IL-1 Ra (×10⁴)	23.81 ± 11.25§	22.13 ± 81.37	113.67 ± 73.65	NS

Data are expressed as mean picograms per milliliter.

* NS = no significant within group differences by ANOVA and no significant differences between the prestimulation concentration and either poststimulation concentration or between the 1- and 5-minute poststimulation concentrations, by the Wilcoxon test.

† $P = 0.01$ compared with MGD; $P = 0.006$ compared with SS ATD (Table 2).

‡ $P = 0.03$ compared with MGD; $P = 0.05$ compared with SS ATD (Table 2).

§ $P = 0.01$ compared with MGD; $P = 0.04$ compared with SS ATD (Table 2).

immediately after tear collection (model GA110 scale; Ohaus, Florham Park, NJ). Wicks were then placed into the end of a micropipette tip located within a 0.5-ml tube (Eppendorf, Fremont, CA) as described by Jones et al.[40] For experiments evaluating the concentrations of IL-1 cytokines in reflex tear fluid, an unstimulated tear fluid sample was collected, and reflex tearing was induced by placing a dry cotton-tipped applicator under the middle nasal turbinate, advancing it until the nasal membrane of the ethmoid sinus was reached, then rotating it for 1 minute as previously described.[41] Tear fluid was then collected from the ipsilateral eye 1 and 5 minutes after stimulation.

Tears were extracted from the saturated wicks by centrifuging them at 12,000 rpm for 5 minutes within the pipette tip after adding a volume of buffer (50 mM Tris/HCl, 0.15 M NaCl, 10 mM CaCl₂, 0.005% Brij35, 0.02% sodium azide [pH 7.5]) 10 times greater than the original volume of the tear sample. The rods and pipette tips were carefully removed and the tear fluid aspirated. Tear fluid from both eyes was combined. This method resulted in a final tear dilution factor of 1:11 for the ELISA, gelatin zymography, and the MMP-9 activity assay. Tear samples were placed in numbered 500-μl tubes (Eppendorf) and stored at −80°C for 3 to 7 days until they were used.

Subjects with dry eye were not receiving any eye treatment other than nonpreserved artificial tears, and they were instructed not to instill any eye drops on the day the tear collection was performed. Tear collection was repeated on a separate day in all subjects, and both tear collections were performed in the morning. Tear fluid from one tear collection was used for cytokine ELISAs, and tear fluid from the second collection was used for the lactoferrin ELISA, gelatin zymography, and the MMP-9 activity assay.

IL-1α, -1β, and -1Ra and Lactoferrin ELISAs

The concentrations of IL-1 family cytokines were determined with commercial ELISA kits. For these assays, tear samples were diluted in ELISA buffer (supplied by the manufacturer) to a final volume of 100 to 200 μl. These assays were performed as recommended by the manufacturer. Tear lactoferrin concentration was measured with an immunoassay (Touch Tear MicroAssay System; Touch Scientific, Raleigh, NC).

Gelatin Zymography and MMP-9 Activity Assay

Gelatinase level in the tear fluid was measured by gelatin zymography, as previously described.[11] Diluted tear samples (all at a dilution of 1:11) were incubated with SDS-gel sample buffer for 30 minutes at room temperature and analyzed by electrophoresis on a 10% SDS-polyacrylamide gel containing 1 mg/ml gelatin. After electrophoresis, the proteins were renatured by removing SDS from the gel using two washes of 0.25% Triton X-100 (30 minutes per wash). This was followed by an 18-hour incubation at 37°C in the digestion buffer consisting of 50 mM Tris-HCl (pH 7.4) containing 0.15 M NaCl, 10 mM CaCl₂, 2 μM ZnSO₄, 1 mM phenylmethylsulfonyl fluoride (PMSF), 0.005% Brij35, and 0.02% sodium azide. After this incubation, the gel was briefly rinsed in distilled water and stained with 0.25% Coomassie brilliant blue R250 prepared in 40% isopropanol solution for 1 hour. The gel was destained with 7% acetic acid. Gelatinase activity in the gel was visible as a clear area in the blue background, indicating an area where the gelatin had been digested. The minimum sensitivity of this technique for detecting gelatinase B is 0.05 ng/lane. The molecular weight of gelatinases in the tear fluid was determined from molecular weight standards (prestained broad range standards; Bio-Rad, Hercules, CA) and 0.1 ng purified rabbit 92-kDa progelatinase B (Oncogene Research, Cambridge, MA) that were run in separate lanes on the gel. These gels were photographed with a camera (Polaroid, Cambridge, MA), and the photographs were scanned (Scan Jet 4C scanner; Hewlett-Packard, Palo Alto, CA) into a computer.


FIGURE 2. Lactoferrin concentration in tears from normal subjects, patients with MGD, and patients with SS ATD. *$P < 0.01$ compared with patients with SS.

FIGURE 3. Gelatin zymogram of tear samples from a normal subject, two patients with MGD, a patient with non-SS ATD, and two patients with SS ATD. The 92-kDa pro-MMP-9 and 72-kDa pro-MMP-2 bands are marked. Sample SS2 (*right lane*) was obtained from a 75-year-old patient with SS who had a 30-year history of bilateral recurrent sterile corneal ulceration with perforation.

MMP-9 activity in tear fluid was measured with an MMP-9 activity assay system (Biotrak; Amersham Pharmacia Biotech, Piscataway, NJ), according to a previously published protocol.[42] This colorimetric assay captures MMP-9 in the tear fluid and measures its activity in cleaving a modified prodetection enzyme and the subsequent cleavage of its chromogenic peptide substrate.[43]

Immunofluorescent Staining of Conjunctival Impression Cytology and Conjunctival Biopsy Specimens

Impression Cytology. The expression of four forms of IL-1 (IL-1α, precursor and mature IL-1β, and IL-1Ra) was evaluated in conjunctival impression cytology specimens obtained from 6 ideal normal subjects and 16 patients with SS ATD.

Impression cytology was performed by lightly pressing a membrane (Biopore; Millipore, Bedford, MA) against the nasal, inferior, and temporal bulbar conjunctiva, 1 mm behind the limbus after instillation of topical anesthesia (0.5% proparacaine hydrochloride). The membranes were placed in a container and stored at $-80°C$ until they were processed. Before staining, these membranes were fixed with cold methanol for 10 minutes and were then blocked for 20 minutes with PBS containing 2% fetal bovine serum (FBS) to prevent nonspecific staining. The cytology specimens obtained from the nasal and temporal bulbar conjunctiva were bisected, and one of the four primary antibodies (IL-1α, precursor and mature IL-1β and -1Ra) was applied to

each membrane for 1 hour at room temperature in a moist chamber. Membranes were rinsed three times with PBS and incubated for 1 hour with FITC-conjugated secondary antibody. The cytology specimens obtained from the inferior bulbar conjunctiva was treated only with secondary antibody and served as a negative control. Membranes were washed three times with PBS, placed on a glass microscope slide, and covered with nonfade mounting medium (Fluoromount-G; Southern Biotechnology Associates, Birmingham, AL) and a glass coverslip. Specimens were examined and photographed with a microscope (Axiophot II; Nikon, Tokyo, Japan) using TMAX 400 film (Eastman Kodak, Rochester, NY). The fluorescein staining was visually graded negative if the staining was less than or equal to the secondary antibody control and positive if it was greater than the secondary antibody control by two independent observers.

Conjunctival Biopsy. Samples were taken from the superior or superotemporal bulbar conjunctiva of three normal subjects with Schirmer 1 test scores of 15 mm or more, no corneal fluorescein staining, and no lid or conjunctival inflammation, and three patients with SS KCS during cataract surgery. Tissue specimens were placed in DMEM (Life Technologies, Gaithersburg, MD) for transport and then were embedded in optimal cutting temperature (OCT) compound (Tissue Tek, Elkhart, IN), rapidly frozen in liquid nitrogen, and stored at $-70°C$. Within 72 hours, serial 4- to 5-μm-thick sections were cut. Indirect immunofluorescence staining on tissue sections was performed by a previously reported technique,[44] using polyclonal anti-


FIGURE 4. MMP-9 activity in tear samples of normal subjects, patients with MGD, and patients with SS ATD, measured by an MMP-9 activity assay. *$P < 0.001$ compared with normal subjects.

TABLE 4. Expression of IL-1 Cytokines in Conjunctival Impression Cytology Specimens from Normal Subjects and Patients with SS KCS

	Normal Eyes		SS KCS		
Antibodies	**Eyes (n)**	**%**	**Eyes (n)**	**%**	**P ***
IL-1α					
Negative	6	100	5	31.25	
Positive	0	0	11	68.75	0.012
Total	6	100	16	100	
Precursor IL-1β					
Negative	2	33.33	0	0	
Positive	4	66.67	15	100	0.071
Total	6	100	15	100	
Mature IL-1β					
Negative	4	66.67	1	6.25	
Positive	2	33.33	15	93.75	0.009
Total	6	100	16	100	
IL-1 Ra					
Negative	6	100	8	50	
Positive	0	0	8	50	0.051
Total	6	100	16	100	

* Fisher exact test.

bodies for IL-1α, -1β, and -1Ra at a concentration of 50 μg/ml and FITC-labeled secondary antibodies. The specificity of these antibodies was evaluated by neutralization with their corresponding recombinant human cytokine proteins according to the manufacturer's instructions. Primary antibodies were incubated for 1 hour at 37°C (0.002 μg/ml anti-IL-1α or anti-IL-1β antibodies with 50 pg/ml of their respective recombinant proteins and 1 μg/ml anti-IL-1Ra antibody with 50 ng/ml of its recombinant protein), before applying the mixture to tissue sections. Some sections were treated with the secondary antibody alone as a negative control. Slides were photographed as for the assays described earlier.

Statistics

Student's *t*-test or Mann-Whitney test were used when appropriate for comparing the ELISA results between groups. One-way ANOVA and Wilcoxon paired tests were used to compare pre- and poststimulation tear cytokine concentrations. The ELISA data are expressed as means ± SD, and the differences were considered statistically significant at $P < 0.05$. The *t*-distribution was used to determine whether correlation coefficients were different from zero.[45]

RESULTS

Profile of IL-1 Cytokines in Tear Fluid

The concentrations of the IL-1 family of cytokines in basal tear fluid collected from normal subjects and patients with MGD and SS ATD are presented in Table 2. The concentration of IL-1α was significantly higher in the tear fluid of both dry-eye groups than in the normal group. The precursor form of IL-1β was the predominant form of this cytokine in normal tear fluid with a mean precursor-to-mature ratio of 19.1 ± 14.2. IL-1Ra was also detected in normal tear fluid with a ratio to IL-1α and precursor IL-1β of more than 27,000 and more than 40,000, respectively. Compared with normal eyes, there was a statistically significant increase in the concentration of mature IL-1β and a decrease in the concentration of precursor IL-1β in the tear fluid of patients with MGD and SS ATD. These changes resulted in significantly lower ratios of the precursor-to-mature forms of IL-1β in both dry-eye groups. There was no significant difference in the concentration of IL-1Ra among the three

groups; however, the ratio of IL-1Ra to IL-1α was significantly lower in the two dry-eye groups and the IL-1Ra-to-IL-1β ratio was significantly decreased in the MGD group compared with the control group. A strong correlation was observed between the clinical intensity of corneal fluorescein staining and the log of the tear IL-1α concentration (Fig. 1A) and between the corneal fluorescein staining score and the precursor-mature IL-1β ratio (Fig. 1B).

Concentrations of IL-1 Cytokines in Reflex Tear Fluid

One minute after stimulation of the nasal mucosa, a 1.5-fold decrease of the tear fluid IL-1α concentration, a 7.7-fold decrease in precursor IL-1β concentration, and a minimal decrease in IL-1Ra concentration was observed. However, 5 minutes after stimulation, the concentrations of all three cytokines increased compared with the 1-minute levels: IL-1α (threefold), IL-1β (fourfold), and IL-1Ra (fivefold). Within-group (ANOVA) and paired (Wilcoxon test) comparisons between the prestimulation concentration and either the poststimulation concentration or between the 1 and 5 minute poststimulation concentrations were not statistically significant (Table 3). Because the concentration of mature IL-1β was near or below the level of detection of our immunoassay in unstimulated and stimulated tear fluid obtained from these normal subjects, no meaningful statistical comparison could be made.

Lactoferrin Concentration in Tear Fluid

The tear fluid concentration of lactoferrin was 1.35 ± 0.07 μg/ml in normal subjects, 1.16 ± 0.16 μg/ml in patients with MGD (no significant difference), and 0.08 ± 0.04 μg/ml in patients with SS ($P = 0.001$ when compared with either normal subjects or MGD; Fig. 2).

MMP-9 Level and Activity in Tear Fluid

Minimal or no 92-kDa pro-MMP-9 was observed by gelatin zymography of tear fluid samples taken from normal control subjects (representative sample shown in Fig. 3, left lane). In contrast, greater levels of pro-MMP-9 were found in tear fluid samples taken from patients with dry eye who had MGD, patients with non-SS ATD, and those with SS (Fig. 3). The strongest bands were observed in a 75-year-old patient with SS who had a 30-year history of bilateral recurrent sterile corneal ulceration with perforation (Fig. 3, right lane, SS2).

To confirm the zymography results, a quantitative MMP-9 activity assay detected an activity of 7.2 ± 2.1 U/mg in normal control subjects, which was significantly increased to 473.1 ± 173.5 U/mg in patients with MGD (66-fold, $P < 0.0001$) and to 651.7 ± 208.3 U/mg in patients with SS (90-fold, $P < 0.0001$; Fig. 4).

Immunostaining of the IL-1 Cytokines in Conjunctival Impression Cytology Specimens

Impression cytology was used to evaluate the relative levels of expression of IL-1α, precursor IL-1β, mature IL-1β, and IL-1Ra in apical conjunctival epithelium specimens obtained from six ideal normal subjects and 16 patients with SS KCS by impression débridement with a membrane (Biopore; Millipore). IL-1α and -1Ra could not be immunodetected in the normal conjunctival epithelium, and the mature form of IL-1β was detected in only 33% of normal samples. Positive immunofluorescent staining for IL-1α, mature IL-1β, and IL-1Ra was observed in a significantly greater percentage of conjunctival cytology specimens from eyes with SS ATD than in those from normal eyes ($P < 0.01$ for IL-1α, $P < 0.009$ for mature IL-1β, and $P < 0.05$ for IL-1Ra; Table 4, Fig. 5).

FIGURE 5. Expression of the IL-1 family of cytokines in apical conjunctival epithelial impression cytology samples from normal subjects and patients with SS ATD. (A, B) Staining with IL-1α–specific antibody in cytology membranes from normal (A) and SS ATD (B) eyes; (C, D) staining with precursor IL-1β–specific antibody in cytology membranes from normal (C) and SS ATD (D) eyes; (E, F) staining with mature IL-1β–specific antibody in cytology membranes from normal (E) and SS ATD (F) eyes; (G, H) staining with IL-1Ra–specific antibody in cytology membranes from normal (G) and SS ATD (H) eyes. Original magnification, $\times$200.

Immunostaining of the IL-1 Cytokines in Conjunctival Biopsy Specimens

The antibodies for IL-1α and -1Ra stained the epithelial cells in conjunctival specimens obtained from patients with SS, with the strongest staining observed in the superficial cell layers (Figs. 6A, 6G). Isolated IL-1Ra–positive cells were scattered throughout the conjunctival epithelium (Fig. 6G). The identity of these cells could not be determined by phase microscopy; however, their staining pattern was similar to that of inflammatory cells located in the conjunctival stroma just below the epithelial basement membrane. The antibody for IL-1β stained the superficial conjunctival epithelium, although to a lesser degree than IL-1α and -1Ra (Fig. 6D). Immunofluorescent staining for all three forms of IL-1 was markedly reduced after preincubation of these antibodies with their corresponding recombinant cytokine proteins (Figs. 6B, 6E, 6H), which indicates the specificity of the antibodies. Lower intensity staining for IL-1α and -1Ra was still observed in the superficial layers of the conjunctival epithelium after preincubation. This may be attributed to increased concentrations of these cytokines in the tightly compacted superficial metaplastic epithelial cells or to absorption of these cytokines from the tear film. Minimal or no staining was observed in conjunctival specimens stained with the secondary antibody alone (Figs. 6C, 6F, 6I).

No staining above the background level was observed for these three antibodies in conjunctival sections obtained from normal subjects (Fig. 7).

DISCUSSION

In this study we found that IL-1α, the precursor and mature forms of IL-1β, and IL-1Ra are present in normal tear fluid. The anti-inflammatory form, IL-1Ra, was present in tremendous excess compared with the two proinflammatory forms, IL-1α and mature IL-1β. An unexpected finding of this study was that the concentration of three of these cytokines, IL-1α, precursor IL-1β, and IL-1Ra, remained relatively stable in the tear fluid after induction of reflex tearing. This finding suggests that the

SS Conjunctiva

IL-1α

IL-1β

IL-1RA

FIGURE 6. Immunofluorescent staining of a conjunctival specimen from a patient with SS ATD. *Top*: sections stained with IL-1α–specific antibody (**A**) without and (**B**) with preincubation of the antibody with recombinant IL-1α and (**C**) with the secondary antibody alone. *Middle*: sections stained with IL-1β–specific antibody (**D**) without and (**E**) with preincubation of the antibody with recombinant IL-1β and (**F**) with the secondary antibody alone. *Bottom*: sections stained with IL-1Ra–specific antibody (**G**) without and (**H**) with preincubation of the antibody with recombinant IL-1Ra and (**I**) with the secondary antibody alone. The epithelium in sections (**C**), (**F**), and (**I**) is outlined by *dotted lines*. Original magnification, ×200.

lacrimal glands secrete these cytokines. This concept is consistent with studies performed by Tanda et al.[46] that reported that mouse parotid gland acinar epithelial cells synthesize IL-1β, store this cytokine in their secretory granules, and secrete it in response to adrenergic stimulation. The low level of expression of these cytokines that we found in the normal human conjunctiva epithelium also points to the lacrimal gland as a potential source of these cytokines in normal eyes.

Significant differences were observed in the level of the proinflammatory IL-1 cytokines in tear fluid obtained from both dry-eye groups compared with that from the normal groups.

Specifically, the concentrations of IL-1α and mature IL-1β were increased, and the concentration of precursor IL-1β was decreased in tear fluid of the patients with dry eye compared with the mean concentrations of these cytokines in tear fluid obtained from both groups of normal subjects. One possible explanation for these differences is age. Tear fluid samples were obtained from two different groups of normal subjects in our study, one with a significantly lower age than the MGD and SS ATD groups and the other with an average age similar to that of the patients with MGD. Despite the similar age, the latter normal group had significantly different concentrations of

Normal Conjunctiva

IL-1α

IL-1β

IL-1 RA

FIGURE 7. Immunofluorescent staining of a conjunctival specimen taken from a normal subject. *Top*: sections stained with IL-1α–specific antibody (**A**) and with secondary antibody alone (**B**). *Middle*: sections stained with IL-1β–specific antibody (**C**) and with secondary antibody alone (**D**). *Bottom*: sections stained with IL-1Ra–specific antibody (**E**) and with secondary antibody alone (**F**). The epithelium is outlined by *dotted lines*. Original magnification, ×200.

IL-1α and precursor and mature IL-1β than the patients with dry eye. In a previously reported study by our group, we observed that the IL-1 concentration in the tear fluid increases with age, yet the concentration of this cytokine is still significantly lower in age-matched control subjects than in patients with ocular rosacea.[38] Taken together, the findings from these two studies suggest that differences in the concentration of IL-1 cytokines observed between normal subjects and patients with dry eye are not due to age alone and may be related to changes in the ocular surface environment that accompany dry eye. Indeed, this hypothesis is supported by our finding that the tear fluid of IL-1β increases within 4 days of experimentally inducing aqueous tear production in mice with the anticholinergic agent scopolamine.[47]

The biologically inactive precursor IL-1β was the predominant form of this cytokine in normal tear fluid, present at a concentration over 10 times greater than the mature, biologically active form. It is likely that precursor IL-1β remains biologically inactive on the ocular surface until conditions, such as increased protease activity, signal its activation. Intracellular activation of precursor IL-1β occurs primarily by the cysteine protease ICE.[12,48] There is increasing recognition that precursor IL-1β may be released into the extracellular environment where it can be activated by a number of extracellular proteases.[25] Studies have indicated that one of the most efficient proteases that activates precursor IL-1β is MMP-9.[25] In our study MMP-9 activity was significantly higher in the tear fluid of patients with MGD and SS ATD than in normal subjects. We have recently reported that MMP-9 activates recombinant precursor IL-1β, increasing its biological activity in stimulating MMP-1 (interstitial collagenase) and MMP-3 (stromelysin-1) by cultured human keratocytes.[49]

Whether ICE, MMP-9, or other proteases mediate it, conditions on the ocular surface of patients with dry eye appear to promote the conversion of precursor IL-1β to its mature form. We observed a significant decrease in the precursor-mature IL-1β ratio from 19 in normal tear fluid to 1 and 0.4 in tear fluid obtained from patients with MGD and SS ATD, respectively. An increasing percentage of the mature form of IL-1β in the tear fluid showed very strong correlation with the intensity of ocular surface dye staining, suggesting that IL-1β itself, the conditions that favor this conversion, or factors that IL-1β stimulates play an important role in the pathogenesis of KCS.

Normal tear fluid was found to contain high concentrations of the anti-inflammatory form of IL-1 (IL-1Ra) in concentrations 25,000 and 40,000 times greater than both proinflammatory forms. The high concentration of IL-1Ra in the tear fluid may be a natural homeostatic mechanism for preventing inappropriate activation of IL-1–mediated inflammatory events on the ocular surface.[12,19] IL-1Ra functions by competitively inhibiting the binding of the proinflammatory forms of IL-1 to their type 1 signal-transducing receptor that is responsible for initiating the cascade of IL-1–mediated inflammatory events. IL-1Ra must be present in concentrations greatly in excess (15- to 102-fold) of the proinflammatory forms, to be biologically active.[26] The necessity of having such a large excess may be explained by the "spare receptor" effect. Target cells typically express thousands of type I IL-1 receptors, yet the expression of only a few receptors per cell is required to initiate a full biological response.[19,26] Therefore, a large excess of IL-1Ra is required to flood the system to block the occupancy of even a few receptors by IL-1.

IL-1Ra is an inducible gene that is typically upregulated in inflammatory conditions, such as rheumatoid arthritis.[26] We have reported that IL-1Ra is upregulated in human corneal epithelial cultures that have been stimulated with lipopolysaccharide (LPS).[49] As might be expected, we detected an increased concentration of IL-1Ra in the tear fluid of patients

with dry eye and in the conjunctival epithelium of patients with SS KCS. The immunofluorescent staining results in our study (Fig. 6) suggest that some of the IL-1Ra on the ocular surface of patients with SS KCS may be derived from inflammatory cells infiltrating the conjunctival epithelium. Despite the increased level of expression, the ratio of IL-1Ra to IL-1α in both dry-eye groups and the ratio of IL-1Ra to mature IL-1β in patients with MGD was significantly lower than in normal subjects. Reports of placebo-controlled clinical trials in which IL-1Ra was administered to patients with rheumatoid arthritis have noted that increasing the ratio of IL-1Ra to the proinflammatory forms significantly improves clinical symptoms.[50] Additional studies are needed to determine the optimum balance between IL-1Ra and IL-1α and -1β on the ocular surface to suppress IL-1–mediated bioactivity.

References

1. Jones DT, Yen M, Monroy D, Ji X, Atherton SS, Pflugfelder SC. Evaluation of cytokine expression in the conjunctival epithelia of Sjögren's syndrome patients. *Invest Ophthalmol Vis Sci.* 1994;35: 3493–3504.

2. Baudouin C, Brignole F, Becquet F, Pisella PJ, Goguel A. Flow cytometry in impression cytology specimens: a new method for evaluation of conjunctival inflammation. *Invest Ophthalmol Vis Sci.* 1997;38:1458–1464.

3. Brignole F, Pisella PJ, Goldschild M, De Saint Jean M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in conjunctival epithelial cells of patients with dry eyes. *Invest Ophthalmol Vis Sci.* 2000;41:1356–1363.

4. Pflugfelder SC, Huang AJW, Schuclovski PT, Pereira IC, Tseng SCG. Conjunctival cytological features of primary Sjögren's syndrome. *Ophthalmology.* 1990;97:985–991.

5. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment on patients with dry eye: effect on conjunctival lymphocytes. *Arch Ophthalmol.* 2000;118:1489–1496.

6. Raphael M, Bellefqih S, Piette JCH, Le Hoang PH, Debre P, Chomette G. Conjunctival biopsy in Sjögren's syndrome: correlations between histological and immunohistochemical features. *Histopathology.* 1988;13:191–202.

7. Power WJ, Mullaney P, Farrel M, Collum L. Effect of topical cyclosporin A on conjunctival T cells in patients with primary Sjögren's syndrome. *Cornea.* 1993;12:507–511.

8. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren's syndrome. *Ophthalmology.* 1999;106:811–816.

9. Sall K, Stevenson OD, Mundorf TK, Reis BL. CSA phase 3 study group: two multicenter, randomized studies of the efficacy and safety of cyclosporin ophthalmic emulsion in moderate to severe dry eye disease. *Ophthalmology.* 2000;107:631–639.

10. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. *Curr Eye Res.* 1999;19:201–211.

11. Afonso A, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. Tear fluid gelatinase B activity correlates with IL-1α concentration and fluorescein tear clearance. *Invest Ophthalmol Vis Sci.* 1999;40:2506–2512.

12. Dinarello CA. Biologic basis for interleukin-1 in disease. *Blood.* 1996;15:2095–2147.

13. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits, synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. *J Clin Invest.* 1988;81:1162–1172.

14. Jiang Y, Genant HK, Watt I, et al. A multicenter double-blind, dose ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. *Arthritis Rheum.* 2000;43:1001–1009.

15. McDevitt MJ, Wang HY, Konbelman C, et al. Interleukin-1 genetic association with periodontitis in clinical practice. *J Periodontol.* 2000;71:156–163.

16. Rosenbaum JT, Plank ST, Huang XN, Rich L, Ansel JC. Detection of mRNA for the cytokines, interleukin-1α and interleukin-8, in corneas from patients with pseudophakic bullous keratopathy. *Invest Ophthalmol Vis Sci.* 1995;36:2151–2155.

17. Fabre EJ, Bureau J, Pouliquen Y, Lorans G. Binding sites for human interleukin 1α, gamma interferon and tumor necrosis factor on cultured fibroblasts of normal corneas and keratoconus. *Curr Eye Res.* 1991;10:585–592.

18. Shams NB, Reddy CV, Watanabe K, Elgebaly SA, Hanninen LA, Kenyonk R. Increased interleukin-1 activity in the injured vitamin A-deficient cornea. *Cornea.* 1994;13:156–166.

19. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. *N Engl J Med.* 1993;328:106–113.

20. Bankers-Fulbright JL, Kalli KR, McLean DJ. IL-1 signal transduction. *Life Sci.* 1996;59:61–83.

21. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. *N Engl J Med.* 1995;332:1351–1362.

22. Fibbe WE, Daha MR, Hiemstra PS, et al. Interleukin 1 and poly(rI) poly(rC) induce production of granulocyte CSF, macrophage CSF, and granulocyte-macrophage CSF by human endothelial cells. *Exp Hematol.* 1989;17:229–234.

23. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. *FASEB J.* 1991;5:2145–2154.

24. Black RA, Kronheim SR, Sleath PR. Activation of interleukin-1β by a co-induced protease. *FEBS Lett.* 1989;247:386–390.

25. Schonbeck V, Mach F, Libby P. Generation of biologically active IL-1β by matrix metalloproteinase a novel caspase-1 independent pathway of IL-1β processing. *J Immunol.* 1998;161:3340–3346.

26. Arend WP. Interleukin-1 receptor antagonist. *Adv Immunol.* 1993;54:167–223.

27. Dekaris I, Yamada J, Streilein JW, Dana MR. Effect of topical interleukin-1 receptor antagonist (IL-1ra) on corneal allograft survival in presensitized hosts. *Curr Eye Res.* 1999;19:456–459.

28. Wilson SE, Schultz GS, Chesini N, Weng J, Yu-Guang HE. Epidermal growth factor, transforming growth factor alpha, transforming growth factor beta, acidic fibroblast growth factor, basic fibroblast growth factor and interleukin-1 proteins in the cornea. *Exp Eye Res.* 1994;59:63–72.

29. Wilson SE, He YG, Lloyd SA. EGF, EGF receptor, basic FGF, TGF β-1, and interleukin-1α mRNA in human corneal epithelial cells and stromal fibroblasts. *Invest Ophthalmol Vis Sci.* 1992;33:1756–1765.

30. Weng J, Mohan RR, Li Q, Wilson SE. IL-1 upregulates keratinocyte growth factor and hepatocyte growth factor mRNA and protein production by cultured stromal fibroblast cells: interleukin-1β expression in the cornea. *Cornea.* 1997;16:465–471.

31. Kennedy MC, Rosenbaum JT, Brown J, et al. Novel production of interleukin-1 receptor antagonist peptides in normal human cornea. *J Clin Invest.* 1995;95:82–88.

32. Gamache DA, Dimitrijevich SD, Weimer LK, Spellman JM, Graff G, Janni JM. Secretion of proinflammatory cytokines by human conjunctival epithelial cells. *Ocul Immunol Inflamm.* 1997;5:117–128.

33. Nakamura Y, Sotozono C, Kinoshita S. Inflammatory cytokines in normal human tears. *Curr Eye Res.* 1998;17:673–676.

34. Murillo-Lopez F, Pflugfelder SC. Dry eye. In: Krachmer J, Mannis M, Holland E, eds. *The Cornea.* St. Louis: Mosby; 1996:663–686.

35. Kuizenga A, van Haeringen, Kijlstra A. Inhibition of hydroxyl radical formation by human tears. *Invest Ophthalmol Vis Sci.* 1987;28:305–313.

36. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. *N Engl J Med.* 1997;336:1066–1071.

37. Fox RI, Robinson CA, Curd JG, Kozir F, Howell FV. Sjögren's syndrome: proposed criteria for classification. *Arthritis Rheum.* 1986;29:577–585.

38. Barton K, Monroy D, Nava A, Pflugfelder SC. Inflammatory cytokines in tears of patients with ocular rosacea. *Ophthalmology.* 1997;104:1868–1874.

39. Macri A, Pflugfelder S. Correlation of the Schirmer 1 and fluorescein clearance tests with the severity of corneal epithelial and eyelid disease. *Arch Ophthalmol.* 2000;118:1632–1638.

40. Jones DT, Monroy D, Pflugfelder SC. A novel method of tear collection: comparison of glass capillary micropipettes with porous polyester rods. *Cornea.* 1997;16:450–458.

41. Tsubota K. The importance of the Schirmer test with nasal stimulation. *Am J Ophthalmol.* 1991;111:106–108.

42. Sobrin L, Selzer MG, Lokeshwar BL, Pflugfelder SC. Stromelysin (MMP-3) activates pro-MMP-9 secreted by corneal epithelial cells. *Invest Ophthalmol Vis Sci.* 2000;41:1703–1709.

43. Konttinen YT, Halinen S, Hanemaaijer R, et al. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogren's syndrome. *Matrix Biol.* 1998;17:335–347.

44. Liu Z, Pflugfelder SC. Increased expression of the type 1 growth factor receptor family in the conjunctival epithelium of patients with keratoconjunctivitis. *Am. J. Ophthalmol.* 2000;129:472–480.

45. Armitage P. *Statistical Methods in Medical Research.* Oxford, UK: Blackwell Scientific; 1971:160–162.

46. Tanda N, Ohyama H, Yamakawa M, et al. IL-1 beta and IL-6 in mouse parotid acinar cells: characterization of synthesis, storage and release. *Am J Pathol.* 1998;274:G147–G156.

47. Pflugfelder SC, Solomon A, Dursun D, Li D-Q. Dry eye and delayed tear clearance: a call to arms. *Adv Exp Med Biol.* In press.

48. Thornberry NA, Bull HG, Calaycay JR, Chapman K, Howard A, Kostura M. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. *Nature.* 1992;356:768–774.

49. Solomon A, Monroy D, Rosenblatt M, Ji Z, Lokeshwar BL, Pflugfelder SC. Doxycycline inhibition of interleukin-1 in the corneal epithelium. *Invest Ophthalmol Vis Sci.* 2000;41:2544–2557.

50. Dinarello CA. The role of interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. *N Engl J Med.* 2000;343:732–734.